Valproic Acid as a Potential Inhibitor of
Plasmodium falciparum Histone Deacetylase 1 (PfHDAC1):
An in Silico Approach

Mohamed A. Abdallah Elbadawi 1,†, Mohamed Khalid Alhaj Awadalla 2,†,*,
Muzamil Mahdi Abdel Hamid 3, Magdi Awadalla Mohamed 4 and Talal Ahmed Awad 5

1 Department of Pharmacology, Faculty of Pharmacy, University of Khartoum, Khartoum 11111, Sudan; E-Mail: mabadawi@uofk.edu
2 College of Pharmacy, University of Hail, Hail 81451, Saudi Arabia
3 Department of Parasitology and Medical Entomology, Institute of Endemic Diseases, University of Khartoum, Khartoum 11111, Sudan; E-Mail: mahdi@iend.org
4 Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Khartoum, Khartoum 11111, Sudan; E-Mail: mawadalla@uofk.edu
5 Medicinal and Aromatic Plants Research Institute, National Centre of Research, Khartoum 11111 Sudan; E-Mail: talaladlan@hotmail.com

† These authors contributed equally to this work.
* Author to whom correspondence should be addressed; E-Mail: mkaawadalla@yahoo.com or m.awadalla@uoh.edu.sa; Tel.: +966-501-583-589.

Academic Editor: Claudiu T. Supuran

Received: 3 December 2014 / Accepted: 30 January 2015 / Published: 11 February 2015

Abstract: A new Plasmodium falciparum histone deacetylase1 (PfHDAC1) homology model was built based on the highest sequence identity available template human histone deacetylase 2 structure. The generated model was carefully evaluated for stereochemical accuracy, folding correctness and overall structure quality. All evaluations were acceptable and consistent. Docking a group of hydroxamic acid histone deacetylase inhibitors and valproic acid has shown binding poses that agree well with inhibitor-bound histone deacetylase-solved structural interactions. Docking affinity dG scores were in agreement with available experimental binding affinities. Further, enzyme-ligand complex stability and reliability were investigated by running 5-nanosecond molecular dynamics simulations. Thorough analysis of the simulation trajectories has shown that enzyme-ligand complexes
were stable during the simulation period. Interestingly, the calculated theoretical binding energies of the docked hydroxamic acid inhibitors have shown that the model can discriminate between strong and weaker inhibitors and agrees well with the experimental affinities reported in the literature. The model and the docking methodology can be used in screening virtual libraries for \( P/f \)HDAC1 inhibitors, since the docking scores have ranked ligands in accordance with experimental binding affinities. Valproic acid calculated theoretical binding energy suggests that it may inhibit \( P/f \)HDAC1.

**Keywords:** \( P/f \)HDAC1; malaria; valproic acid; histone deacetylase inhibitor, homology model; docking; molecular dynamics; binding energy

1. Introduction

Malaria, the life-threatening parasitic disease, is responsible for 627,000 deaths worldwide annually [1]. In humans, the disease is caused by different *Plasmodium* sp., namely *P. falciparum*, *P. vivax*, *P. ovale*, *P. malariae* and *P. knowlesi*, with *P. falciparum* being the major cause of malaria deaths worldwide [1]. Currently, the World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) as the first line treatment for severe malaria. Nevertheless, the emergence of resistance to ACTs has called for the search for new antimalarials [2].

In eukaryotes, histone deacetylases (HDACs) are part of the epigenetic machinery, which controls important biological processes, like proliferation and differentiation, through the control of gene expression. HDACs regulate chromatin remodeling by removing the acetyl group from the \( \varepsilon \)-amino side chain of several lysine residues of the histone protein, allowing the DNA wrapped around histones to unfold and be accessible for transcription factors. HDACs also regulate gene expression together with some acetylases by deacetylation/acetylation of other non-histone proteins, such as transcription factors [3]. In humans, the HDAC superfamily is classified into four groups based on function and sequence similarity to yeast prototypes: HDAC1, HDAC2, HDAC3 and HDAC8 constitute class I; HDAC4, HDAC5, HDAC6, HDAC7, HDAC9 and HDAC10 belong to class II; HDAC11 is the sole member of class IV; these three groups are related to the zinc-dependent yeast Rpd3 or Hda1, whereas class III is related to the NAD\(^+\)-dependent yeast silent information regulator protein 2 (Sir2), also called sirtuins, and includes Sirt1–Sirt7 [4,5]. In *Plasmodium falciparum*, two HDAC proteins were characterized, *Plasmodium falciparum* histone deacetylase 1 (\( P/f \)HDAC1) and *Plasmodium falciparum* sirtuin 2 (\( P/f \)Sir2), which are homologues to class I and class III, respectively, but none of their structures have been solved [6,7].

Because of their critical role in the regulation of essential biological processes, HDACs are well recognized as a cancer therapy target. The hydroxamic acid-based HDAC inhibitor, suberoylanilide hydroxamic acid (SAHA), is approved in the treatment of cutaneous T-cell lymphoma [8]. There is a promising body of experimental data investigating the effect of HDAC inhibitors, particularly hydroxamic acid derivatives, against several parasites, including *Plasmodium falciparum*, where the HDACs were validated as a therapeutic target, and \( P/f \)HDAC1 is likely the target of hydroxamate inhibitors [9–13].
The old anticonvulsant and mood stabilizer, valproic acid, has been found to inhibit zinc-dependent class I human HDACs [14]. Interestingly, valproic acid was also found to inhibit the *in vitro* growth of *Toxoplasma gondii* and was proven to have HDAC-mediated activity against miracidia of *Schistosoma mansoni* [15,16]. No published experimental data are available for valproic acid inhibition of PfHDAC1, except an unpublished IC$_{50}$ of 100 µM reviewed by Andrews *et al.* [9]. In mammalian cells, the reported IC$_{50}$ of HDAC inhibition by valproic acid was 433–1350 µM compared to 5–20 µM of the licensed drug, SAHA [9]. Considering the promising results currently obtained in clinical trials investigating valproic acid as a potential therapy for different cancers together with the valproic acid maximum dose that can reach 60 mg/kg/day [17–20], we hypothesize that valproic acid may have an activity against PfHDAC1.

In this work, a PfHDAC1 homology model was built, and the model quality was assessed. The model active site architecture has been investigated and evaluated by docking of known hydroxamate PfHDAC1 inhibitors reported in the literature [10]; as seen in Figure 1. Further, valproic acid was docked; the generated docking poses were compared; and the theoretical binding energies were calculated and compared to available experimental data.

**Figure 1.** Two-dimensional structures of the ligands used in docking work. (a) Trichostatin A (TSA); (b) suberoylanilide hydroxamic acid (SAHA); (c) suberoyl bis-hydroxamic acid (SBHA); and (d) valproic acid.
2. Results and Discussion

2.1. Model Building and Refinement

To find a template protein structure for building the PfHDAC1 homology model, the PfHDAC1 sequence obtained from UniprotKB (Accession Number Q7K6A1) was used to query the sequences of structures deposited in the Protein Data Bank (PDB) using the protein Basic Local Alignment Search Tool (BLAST) [21–23]. Human HDAC2 structure (PDB:3MAX) was found to have the highest sequence identity (63%) with PfHDAC1 [24]. Previously, three different PfHDAC1 models were generated using two templates for each: The first was derived from (PDB: 3MAX) and human HDAC8 (PDB: 1T69); the other two models were constructed from the former template and the yeast HDAC-like protein (1C3R) [10,11,25]. The latter two templates share 41% and 31% sequence identity with PfHDAC1, respectively. A multiple sequence alignment of the target and the described templates using ClustalX [26] is shown in the Figure S1, where (PDB: 3MAX) clearly has the highest sequence identity to and coverage of PfHDAC1.

The final intention for building a homology model is to predict an unknown protein structure from its sequence with accuracy comparable to experimentally-solved structures using known protein structure(s). It has been proven that the accuracy of a homology model depends on the target-template sequence similarity: the higher the sequence similarity, the better the model [27]. Therefore, 3MAX was employed to build a new PfHDAC1 model using the SWISS-MODEL online server [28]. The obtained initial model was further refined by molecular dynamics (MD) simulations. The MD simulations’ resulting trajectory contained nineteen structures sampled every 25 ps during the simulation time. The structure with the lowest potential energy was then selected for further work.

2.2. Model Quality

The Molecular Operating Environment software package (MOE) superposition function was used to superpose the refined model and the template. The all-atom root-mean-square deviation (RMSD) between the model and the template (3MAX) was 0.85 Å, which falls within the acceptable range. All atom structure similarity can be viewed from the superposition in Figure 2.

Figure 2. Cartoon representation of homologues superposition. Human histone deacetylase 2 (HDAC2) in blue, Plasmodium falciparum histone deacetylase1 (PfHDAC1) in green and zinc in yellow.
We further investigated the stereochemical accuracy, folding reliability and the overall quality of the model. From the Rampage server [29], 98.1% of residues were found in the favored regions of the obtained Ramachandran plot 1.4% of residues were in the allowed regions; and only two residues (0.5%) were in the plot outlier region (Figure S2). This distribution of the enzyme residues’ (\(\phi,\psi\)) dihedral angles in the plot indicates acceptable stereochemical accuracy. Verify3D-1D differentiates between correct and incorrect protein folding depending on a compatibility score of an amino acid surrounding environment (3D) to its amino acids sequence (1D); a negative score is a sign of serious folding error [30]. From the analysis of the Verify3D result shown in Figure 3, it is clear that residues have positive scores, except for one residue, which highlights the correct model folding.

![Figure 3. Verify3D plot of the Plasmodium falciparum histone deacetylase1 PfHDAC1 homology model.](image)

From Figure 4, obtained from the Protein Structure Assessment (ProSA-web) server, groups of structures solved by X-ray or NMR are shown in distinctive colors, and the obtained model z-score was −8.76, which is placed within the range of scores typically found for native proteins of a similar size [31]. The two residues, in the outlier region in the Ramachandran plot, Ala95 and Gly178, were not matched with any residue from the template structures (i.e., found in the gap region in the multiple alignment shown in Figure S1), which may explain their inaccurate modeling. The same justification could explain the His336 negative score in Verify3D assessment. Interestingly, our single-template model quality assessment results were significantly higher compared to the best and most recent structure obtained from multiple templates, including our single-template 3MAX. The residues in the favored region of the Ramachandran plot were 98.1% for our model, which is significantly higher than the 91% reported for the best model obtained from multiple templates, including our single-template 3MAX [11]. Further, the number of residues in the outlier region was not reported for previous models. Moreover, our model percentage of residues scored ≥0.2 in Verify3D assessment was slightly higher (95.7%) than the best model obtained from multiple templates, including our single-template 3MAX (95%) [11]. To this level,
we conclude that all results are acceptable and consistent, and the model has better assessment results than previously presented models and can be used for further work.

![Protein Structure Assessment server (ProSA-web) result of the Plasmodium falciparum histone deacetylase1 PfHDAC1 homology model; the black dot represents the model z-score.]

2.3. Plasmodium Falciparum Histone Deacetylase1 Model

The MD-refined model comprises a single domain following the α-/β-fold class consisting of an eight-strand β-sheet surrounded by 14 α-helices, which is similar to HDACs homologues from other species, like Schistosoma [32]. The enzyme active site was determined using the Alpha Site Finder embedded in MOE. The Site Finder depends on geometric methods, since no energy models are used. Instead, the relative positions and accessibility of the enzyme atoms are considered along with a rough classification of the chemical type [33]. The method is based on α-spheres, which are clustered to produce a collection of sites ranked according to the number of hydrophobic contacts made with the receptor. When the suggested sites were inspected, the site ranked first was the only one to include the enzyme catalytic Zn\(^{2+}\) that is required to accomplish the biological function of the zinc-dependent HDACs, including PfHDAC1. The first ranked site is therefore selected for further work. The site contains the Zn\(^{2+}\) cofactor involved in the catalysis of the substrate occupies the active site (Figure 5a). The active site has a catalytic triad, where Zn\(^{2+}\) of the free enzyme forms a coordination bond with three amino acids, Asp174, His176 and Asp262 (Figure S3). These residues are highly conserved in Zn\(^{2+}\)-dependent HDACs and correspond to Asp181, His183 and Asp269 of the template. Additional residues involved in the formation of the active site include: Pro25, Met26, Thr96, Asp97, His138, His 139, Gly147, Phe148, Cys149, Tyr202, Phe203, Leu269, Gly298, Gly299 and Tyr301 (Figure 5b).
Figure 5. *Plasmodium falciparum* histone deacetylase1 (PfHDAC1) active site. (a) Gaussian contour of the PfHDAC1 model active site (pink represents hydrogen bonding; green represents hydrophobic contact residues; blue represents mild polar amino acids); and (b) key residues of the model active site.

2.4. Docking

2.4.1. Hydroxamic Acid Inhibitor-PfHDAC1 Complexes

To evaluate the docking capacity of the model, docking of known hydroxamate PfHDAC1 inhibitors reported in the literature was performed [10]. Hydroxamate HDAC inhibitors are composed of a hydroxamic acid group that coordinates zinc; a hydrophobic spacer that extends through the length of the hydrophobic pocket of the HDAC enzyme; and a hydrophobic cap that seals the active site of the HDAC enzyme [8]. All inhibitors were docked in the active site of PfHDAC1, and the structures showed similar ligand-enzyme docking poses presented in Figure 6. The docked inhibitors pose interactions were similar to interactions observed in crystallography-solved homologous structures (Figure S4). In all docked structures, the cofactor Zn$^{2+}$ was pentacoordinated by Asp174, His176 and Asp262 in addition to the ligand bidentate coordination via the carbonyl and the hydroxyl group of the ligands’ hydroxamate; Figure 6. The hydroxyl group of the Tyr301 residue formed a hydrogen bond with the carbonyl oxygen of the ligand’s hydroxamate, while His139 formed a hydrogen bond with the hydroxyl of the hydroxamate moiety in the case of TSA and SBHA; Figure 6a,c. In the case of SAHA, this hydrogen bond was instead donated by His138; Figure 6b. In the enzyme-SAHA complex, Arg97 formed a hydrogen bond with the amide nitrogen of the side group (Figure 6b). This bond was not observed in other ligand enzyme complexes. Mutation studies have shown that His139, Asp174, His176, Asp262 and Tyr301 corresponding residues in human and yeast are important in the substrate catalysis process [34,35]. These residues are responsible for the stabilization of the substrate in the binding site and form part of the charge relay system necessary for the zinc-dependent hydrolysis of the acetylated lysine substrates [36]. Moreover, hydrophobic interactions involved in holding ligands within the active site include: Phe148 and Phe203 formed hydrophobic interactions with SAHA and SBHA; the two
amino acids in addition to Pro25 and Leu268 formed hydrophobic interactions with TSA; Figure 6. Furthermore, the docking affinity $dG$ scores of hydroxamic inhibitors ranked ligands in agreement with the experimentally obtained binding affinities represented as IC$_{50}$ [10] (Table 1).

**Figure 6.** *PfHDAC1* model-ligand interactions. (a) TSA; (b) SAHA; and (c) SBHA. Bond distances are shown in angstroms.

**Table 1.** Binding energy calculated from MD-simulated *PfHDAC1* complexes (kcal·mol$^{-1}$).

| Ligand | IC$_{50}$ (µM) | Score | Binding Energy (kcal·mol$^{-1}$) |
|--------|----------------|-------|---------------------------------|
|        | CQ$^b$ Resistant | CQ$^b$ Sensitive |                              |
| SAHA   | 1.78           | 0.94  | −5.15                          | 280.81 |
| SBHA   | 0.8            | 1.3   | −6.52                          | 281.92 |
| TSA    | 0.008          | 0.11  | −6.92                          | 308.54 |
| Valproic acid | N.A. $^c$ | N.A. $^c$ | −5.13                          | 219.67 |

$^a$ Antiproliferative potencies against *P. falciparum* in vitro obtained from Andrews et al. [10]; $^b$ CQ = chloroquine; $^c$ N.A. = Not available. SAHA: suberoylanilide hydroxamic acid; SBHA: suberoyl bis-hydroxamic acid; TSA: trichostatin A; and CQ: chloroquine.
2.4.2. Valproic Acid-PfHDAC1 Complex

Regarding the valproic acid-enzyme complex, valproic acid showed bidentate coordination with the enzyme Zn$^{2+}$ via the carboxyl carbonyl oxygen and hydroxyl oxygen. Tyr301 and His139 donated hydrogen bonds to the acid carbonyl and hydroxyl oxygen, respectively, which is similar to the coordination fashion observed in the hydroxamic acid derivative enzyme complexes. Enzyme hydrophobic interactions with the molecule alkyl part involved Met26, Phe148 and Phe203, which were also similar to corresponding interactions with the hydroxamate-enzyme complexes (Figure 7).

![Valproic acid-PfHDAC1 complex interactions.](image)

**Figure 7.** Valproic acid-PfHDAC1 complex interactions.

2.5. Molecular Dynamics Simulations

Molecular docking has been successful in binding pose prediction, but it has also failed in expecting binding affinity on many occasions [37,38]. In order to relax the geometries, to get an insight into the stability of the ligand-enzyme complexes and to obtain more reliable binding energies, 5-ns MD simulations were performed on each ligand enzyme complex followed by rigorous MD simulation trajectory analysis. Apart from the other MD simulation objectives mentioned above in this paragraph, from our previous experience in molecular modeling, which agrees with Moonsamy et al. [39], a ligand in even the best docking pose may move away from the binding site within a few picoseconds when subjected to MD simulations. Therefore, we are convinced that any docking calculations not followed by MD simulations at least for hundreds of picoseconds are less reliable.

The Cα-RMSD of each enzyme ligand complex MD simulation trajectory versus time is shown in Figure 8. The average RMSDs of Cα positions along simulation trajectories versus the time of each
structure trajectory were 1.10, 1.17, 1.32 and 1.24 Å for TSA, SAHA, SBHA and valproic acid enzyme complexes, respectively.

![Figure 8](image.png)

**Figure 8.** Root-mean-square deviation (RMSD) of Cα atoms of enzyme-ligand complexes versus time.

The potential energy of each enzyme-ligand complex along the 5-ns simulation period showed that the complexes equilibrated within a maximum of about 500 ps. Once the equilibration time point was passed, the potential energy had plateaued, and the variability as below 800 kcal·mol$^{-1}$ along the remaining 4500 ps simulation time, as shown in Figure 9. The RMSD values together with the MD steady potential energies during simulations imply that the enzyme ligand complex systems have good stability and reliability.

### 2.6. Theoretical Binding Energies

The calculated theoretical binding energies of ligands obtained in this work and their corresponding IC$_{50}$ from *P. falciparum in vitro* growth inhibition assays obtained from the literature [10] are presented in Table 1. The calculated binding energies are in good agreement with the ligands’ IC$_{50}$ values. No corresponding experimental data are available for comparison with valproic acid. The calculated binding energy of valproic acid (219.67 kcal·mol$^{-1}$) was around 72% of the highest calculated TSA binding energy value and 79% of the approved anticancer SAHA (Table 1).
3. Materials and Methods

3.1. Homology Modeling

The FASTA format of the 449 amino acid sequence of PfHDAC1 was retrieved from the UniprotKB database (Accession Number Q7K6A1) [21]. BLAST searching was performed to obtain the template with the highest sequence identity to PfHDAC1 [23]. Human HDAC-2 (PDB: 3MAX) was found to have the highest sequence identity with PfHDAC1 [24]. The sequence of PfHDAC1 together with 3MAX was submitted to the SWISS-MODEL server for homology model building [28].

3.2. Model Refinement

The SWISS-MODEL-generated model was further refined by MD simulations using the YASARA program [40], employing the molecular dynamics macro (md_refine). In brief, the model was subjected to MD simulations using the YASARA2 force-field for 500 ps at 298° K using the NVT canonical ensemble. The default simulation parameters defined by the macro were used during the simulations. The detailed MD refinement procedure was described elsewhere [41].

3.3. Model Quality Validation

The quality of the model was carefully examined using different bioinformatics online tools. The Ramachandran (\(\phi, \psi\)) dihedral angle plot generated by the RAMPAGE server [29] was used to evaluate the model stereochemical quality. The Verify3D server [30] was employed to check the model folding reliability. ProSA-web (z-score) was used to check the overall quality of the 3D model [31].
3.4. Ligands Preparation

MOE software was used for ligand preparation [42]. All ligand structures were obtained from the PubChem database: TSA (CID 444732), suberoylanilide hydroxamic acid (SAHA) (CID 5311), suberoyl bis-hydroxamic acid (SBHA) (CID 5173) and valproic acid (CID 3121). Ligand structures are shown in Figure 1. The protonation state of hydroxamic acid complexes with Zn\textsuperscript{2+} in the active site of zinc-dependent HDACs is controversial. Experimentally, it is difficult to determine the position of the proton directly. However computational studies suggest negative hydroxamate in the active site [43,44], while another study suggests a neutral hydroxamic acid inhibitor [45]. A recent study’s results have strongly suggested negative hydroxamate-Zn\textsuperscript{2+} coordination and explained several experimental observations [46]. Therefore, hydroxamic acid inhibitors and valproic acid 3D structures were imported together in a single MOE database, and thereafter, their hydroxyl groups were deprotonated. The generated hydroxamates and valproate were energy minimized to within an rms gradient of 0.1 kcal·mol\textsuperscript{-1}·Å\textsuperscript{-1} using the MMFF94x force-field [47].

3.5. Docking

All molecular docking of ligands into \textit{PfHDAC1} was performed using MOE [42]. Potential binding sites in the homology model were recognized using the Alpha Site Finder [48]. Once the active site was identified, ligands were docked into the selected site using the triangle matcher placement method [42]. Thirty poses were retained for each ligand and scored using the London \(\Delta G\) function [42]. The retained poses were further refined by energy minimization to 0.1 rms·kcal·mol\textsuperscript{-1}·Å\textsuperscript{-1} using the CHARMM27 molecular mechanics force field [49] and rescored using the affinity \(\Delta G\) scoring function [42]. In the docking, the flexible-ligand rigid-protein approach was employed, where flexible ligand conformations were generated using the Monte Carlo algorithm. The pose with the best refining score of each ligand was selected for further work.

3.6. Molecular Dynamics Simulation

Independent molecular dynamics simulations of all ligand-enzyme complex structures were performed using the YASARA program [40]. All structures’ geometry was minimized to within an rms gradient of 0.1 kcal·mol\textsuperscript{-1}·Å\textsuperscript{-1} using the AMBER99 force-field [50]. All systems were independently contained in a simulation cell of 79.98 × 79.98 × 79.98 Å surrounded by periodic boundary conditions and solvated with water TIP3P molecules [51], and thereafter, simulated annealing minimization of the solvent was performed. Residue protonation states were assigned in relation to calculated p\textit{K}_a values and physiologic simulation, pH 7.4 [52]. Sodium and chloride ions were randomly added to the solvated structures to neutralize the cell and achieve a 0.9% NaCl ion mass fraction (physiological condition). To relax the structures geometry, 5-ns MD simulations were performed and followed by a final energy minimization step. MD simulations were performed at 298 K using the NVT canonical ensemble. The simulations were performed in multiple time steps of 1.25 fs for intramolecular forces and 2.5 fs for intermolecular forces. The particle mesh Ewald method at a cutoff of 7.86 Å was used for long range electrostatic force calculations [53]. MD simulations were sampled every 25 ps, resulting in 200 snapshot trajectories.
3.7. Ligand-Enzyme Complex Theoretical Binding Energy Calculation

In YASARA, theoretical binding energy is obtained by calculating the unbound ligand energy at infinite distance and subtracting the energy of the bound state. A larger positive binding energy is defined in this context as a more favorable binding for a given force-field [40,54]. All theoretical binding energies were calculated after MD simulations and final energy minimization.

4. Conclusions

A homology model of PfHDAC1 based on the crystal structure of human HDAC2 is presented. The model was reliable in terms of stereochemical accuracy, folding reliability and overall correctness assessed by online bioinformatics tools. The model quality was better than previously presented models. The model has shown similar binding site residues observed in zinc-dependent HDAC from other species. Docking affinity \( dG \) scores agreement with the corresponding experimental IC\(_{50}\) obtained from the literature implies that the model and the docking methodology are dependable and can be used to screen virtual compound libraries for PfHDAC1 inhibitors. In this work, MD simulations supported the reliability and stability of the docking poses and reinforced the theoretical binding energy calculations. The valproic acid calculated theoretical binding energy suggests that it is rational to extend studying this drug \textit{in vitro} and in malaria mouse model as a potential PfHDAC1 inhibitor, particularly when taking into account the high maximum dose of the drug. Currently, we are investigating the effect of valproic acid on \( P. falciparum \) growth \textit{in vitro} and in mice infected with \( P. berghei \), which causes rodent malaria.

Supplementary Materials

Supplementary materials can be found at http://www.mdpi.com/1422-0067/16/02/3915/s1.

Acknowledgments

The Deanship of Scientific Research, University of Hail and the Faculty of Pharmacy, University of Khartoum are acknowledged for financial support.

Author Contributions

Mohamed A. Abdallah Elbadawi, Mohamed Khalid Alhaj Awadalla, Muzamil Mahdi Abdel Hamid and Magdi Awadalla Mohamed conceived and designed the study; Mohamed A. Abdallah Elbadawi, Mohamed Khalid Alhaj Awadalla, and Talal Ahmed Awad performed the experiments; Mohamed A. Abdallah Elbadawi, Mohamed Khalid Alhaj Awadalla and Magdi Awadalla Mohamed interpreted the results; Mohamed A. Abdallah Elbadawi and Mohamed Khalid Alhaj Awadalla wrote the manuscript; Muzamil Mahdi Abdel Hamid and Magdi Awadalla Mohamed supervised the study. All authors revised and approved the manuscript.

Conflicts of Interest

The authors declare no conflict of interest.
References

1. World Malaria Report 2013. Available online: http://www.who.int/malaria/publications/world_malaria_report_2013/en/ (accessed on 1 June 2014).

2. Ashley, E.A.; Dhorda, M.; Fairhurst, R.M.; Amaratunga, C.; Lim, P.; Suon, S.; Sreng, S.; Anderson, J.M.; Mao, S.; Sam, B.; et al. Spread of artemisinin resistance in *Plasmodium falciparum* Malaria. *N. Engl. J. Med.* 2014, 371, 411–423.

3. Glozak, M.A.; Sengupta, N.; Zhang, X.; Seto, E. Acetylation and deacetylation of non-histone proteins. *Gene* 2005, 363, 15–23.

4. Yang, X.-J.; Seto, E. The Rpd3/Hda1 family of lysine deacetylases: From bacteria and yeast to mice and men. *Nat. Rev. Mol. Cell Biol.* 2008, 9, 206–218.

5. Marks, P.A.; Breslow, R. Dimethyl sulfoxide to vorinostat: Development of this histone deacetylase inhibitor as an anticancer drug. *Nat. Biotechnol.* 2007, 25, 84–90.

6. Andrews, K.T.; Tran, T.N.; Lucke, A.J.; Kahnberg, P.; Le, G.T.; Boyle, G.M.; Gardiner, D.L.; Skinner-Adams, T.; Fairlie, D.P. Potent antimalarial activity of histone deacetylase inhibitor analogues. *Antimicrob. Agents Chemother.* 2008, 52, 1454–1461.

7. Sumanadasa, S.D.M.; Goodman, C.D.; Lucke, A.J.; Skinner-Adams, T.; Sahama, I.; Haque, A.; Do, T.A.; McFadden, G.I.; Fairlie, D.P.; Andrews, K.T. Antimalarial activity of the anticancer histone deacetylase inhibitor SB939. *Antimicrob. Agents Chemother.* 2012, 56, 3849–3856.

8. Andrews, K.T.; Tran, T.N.; Wheatley, N.C.; Fairlie, D.P. Targeting histone deacetylase inhibitors for anti-malarial therapy. *Curr. Top. Med. Chem.* 2009, 9, 292–308.

9. Phiel, C.J.; Zhang, F.; Huang, E.Y.; Guenther, M.G.; Lazar, M.A.; Klein, P.S. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. *J. Biol. Chem.* 2001, 276, 36734–36741.

10. Jones-Brando, L.; Torrey, E.F.; Yolken, R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of *Toxoplasma gondii*. *Schizophr. Res.* 2003, 62, 237–244.

11. Azzi, A.; Cosseau, C.; Grunau, C. *Schistosoma mansoni*: Developmental arrest of miracidia treated with histone deacetylase inhibitors. *Exp. Parasitol.* 2009, 121, 288–291.
17. Wheler, J.J.; Janku, F.; Falchook, G.S.; Jackson, T.L.; Fu, S.; Naing, A.; Tsimberidou, A.M.; Moulder, S.L.; Hong, D.S.; Yang, H.; et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. *Cancer Chemother. Pharmacol.* **2014**, *73*, 495–501.

18. Tassara, M.; Döhner, K.; Brossart, P.; Held, G.; Götze, K.; Horst, H.-A.; Ringhofer, M.; Köhne, C.-H.; Kremers, S.; Raghavachar, A.; et al. Valproic acid in combination with all-trans retinoic acid and intensive induction therapy for acute myeloid leukemia in older patients. *Blood* **2014**, *123*, 4027–4036.

19. Chu, B.F.; Karpenko, M.J.; Liu, Z.; Aimiuwu, J.; Villalona-Calero, M.A.; Chan, K.K.; Grever, M.R.; Otterson, G.A. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. *Cancer Chemother. Pharmacol.* **2013**, *71*, 115–121.

20. FDA Depakote (divalproex sodium) Tablets for Oral use FDA Approved Labeling Text dated October 7, 2011. NDA 018723/S-037/S-040/S-043/S-045/S-046 Depakote (divalproex sodium) Tablets for Oral use FDA Approved Labeling Text dated 7 October 2011. Available online: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/018723s037lbl.pdf (accessed on 3 May 2014).

21. The UniProt Consortium. The UniProt consortium activities at the universal protein resource (UniProt). *Nucleic Acids Res.* **2014**, *42*, D191–D198.

22. Berman, H.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The protein data bank. *Nucleic Acids Res.* **2000**, *28*, 235–242.

23. Altschul, S.F.; Madden, T.L.; Schäffer, A.A.; Zhang, J.; Zhang, Z.; Miller, W.; Lipman, D.J. Gapped BLAST and PSI-BLAST: A new generation of protein database search programs. *Nucleic Acids Res.* **1997**, *25*, 3389–3402.

24. Bressi, J.C.; Jennings, A.J.; Skene, R.; Wu, Y.; Melkus, R.; de Jong, R.; O’Connell, S.; Grimshaw, C.E.; Navre, M.; Gangloff, A.R. Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. *Bioorg. Med. Chem. Lett.* **2010**, *20*, 3142–3145.

25. Mukherjee, P.; Pradhan, A.; Shah, F.; Tekwani, B.L.; Avery, M.A. Structural insights into the *Plasmodium falciparum* histone deacetylase 1 (PfHDAC-1): A novel target for the development of antimalarial therapy. *Bioorg. Med. Chem.* **2008**, *16*, 5254–5265.

26. Larkin, M.A.; Blackshields, G.; Brown, N.P.; Chenna, R.; McGettigan, P.A.; McWilliam, H.; Valentin, F.; Wallace, I.M.; Wilm, A.; Lopez, R.; et al. Clustal W and Clustal X version 2.0. *Bioinformatics* **2007**, *23*, 2947–2948.

27. Rost, B. Twilight zone of protein sequence alignments. *Protein Eng.* **1999**, *12*, 85–94.

28. Arnold, K.; Bordoli, L.; Kopp, J.; Schwede, T. The SWISS-MODEL workspace: A web-based environment for protein structure homology modelling. *Bioinformatics* **2006**, *22*, 195–201.

29. Lovell, S.C.; Davis, I.W.; Adrencall, W.B.; de Bakker, P.I.W.; Word, J.M.; Prisant, M.G.; Richardson, J.S.; Richardson, D.C. Structure validation by Cα geometry: ϕ, ψ and Cβ deviation. *Proteins-Struct. Funct. Genet.* **2003**, *50*, 437–450.

30. Eisenberg, D.; Lüthy, R.; Bowie, J.U. Verify3D: Assessment of protein models with three-dimensional profiles. *Methods Enzymol.* **1997**, *277*, 396–406.

31. Wiederstein, M.; Sippl, M.J. ProSA-web: Interactive web service for the recognition of errors in three-dimensional structures of proteins. *Nucleic Acids Res.* **2007**, *35*, W407–W410.
32. Marek, M.; Kannan, S.; Hauser, A.-T.; Moraes Mourão, M.; Caby, S.; Cura, V.; Stolfa, D.A.; Schmidtkunz, K.; Lancelot, J.; Andrade, L.; et al. Structural basis for the inhibition of histone deacetylase 8 (HDAC8), a key epigenetic player in the blood fluke Schistosoma mansoni. PLoS Pathog. 2013, 9, e1003645.

33. Labute, P.; Santavy, M. Locating Binding Sites in Protein Structures. Available online: http://www.chemcomp.com/journal/sitefind.htm (accessed on 15 January 2015).

34. Hassig, C.A. A role for histone deacetylase activity in HDAC1-mediated transcriptional repression. Proc. Natl. Acad. Sci. USA 1998, 95, 3519–3524.

35. Kadosh, D.; Struhl, K. Histone deacetylase activity of Rpd3 is important for transcriptional repression in vivo. Genes Dev. 1998, 12, 797–805.

36. Lombardi, P.M.; Cole, K.E.; Dowling, D.P.; Christianson, D.W. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes. Curr. Opin. Struct. Biol. 2011, 21, 735–743.

37. Sousa, S.F.; Fernandes, P.A.; Ramos, M.J. Protein-ligand docking: Current status and future challenges. Proteins 2006, 65, 15–26.

38. Cheng, T.; Li, Q.; Zhou, Z.; Wang, Y.; Bryant, S.H. Structure-based virtual screening for drug discovery: A problem-centric review. AAPS J. 2012, 14, 133–141.

39. Moonsamy, S.; Dash, R.C.; Soliman, M.E.S. Integrated computational tools for identification of CCR5 antagonists as potential HIV-1 entry inhibitors: Homology modeling, virtual screening, molecular dynamics simulations and 3D QSAR analysis. Molecules 2014, 19, 5243–5265.

40. Krieger, E. Yet Another Scientific Artificial Reality Application (YASARA). 2004. http://www.yasara.org/.

41. Krieger, E.; Joo, K.; Lee, J.; Lee, J.; Raman, S.; Thompson, J.; Tyka, M.; Baker, D.; Karplus, K. Improving physical realism, stereochemistry, and side-chain accuracy in homology modeling: Four approaches that performed well in CASP8. Proteins 2009, 77, 114–122.

42. Chemical Computing Group Inc. Molecular Operating Environment (MOE). 2008. http://www.chemcomp.com/.

43. Wang, D.; Helquist, P.; Wiest, O. Zinc binding in HDAC inhibitors: A DFT study. J. Org. Chem. 2007, 72, 5446–5449.

44. Vanommeslaeghe, K.; de Proft, F.; Loverix, S.; Tourwé, D.; Geerlings, P. Theoretical study revealing the functioning of a novel combination of catalytic motifs in histone deacetylase. Bioorg. Med. Chem. 2005, 13, 3987–3992.

45. Wu, R.; Lu, Z.; Cao, Z.; Zhang, Y. Zinc chelation with hydroxamate in histone deacetylases modulated by water access to the linker binding channel. J. Am. Chem. Soc. 2011, 133, 6110–6113.

46. Chen, K.; Zhang, X.; Wu, Y.-D.; Wiest, O. Inhibition and mechanism of HDAC8 revisited. J. Am. Chem. Soc. 2014, 136, 11636–11643.

47. Halgren, T.A. MMFF VI. MMFF94s option for energy minimization studies. J. Comput. Chem. 1999, 20, 720–729.

48. Edelsbrunner, H. Weighted Alpha Shapes; Department of Computer Science, University of Illinois: Champaign, IL, USA, 1995.

49. Mackerell, A.D.; Feig, M.; Brooks, C.L. Extending the treatment of backbone energetics in protein force fields: Limitations of gas-phase quantum mechanics in reproducing protein conformational distributions in molecular dynamics simulations. J. Comput. Chem. 2004, 25, 1400–1415.
50. Wang, J.; Cieplak, P.; Kollman, P.A. How well does a restrained electrostatic potential (RESP) model perform in calculating conformational energies of organic and biological molecules? *J. Comput. Chem.* **2000**, *21*, 1049–1074.

51. Jorgensen, W.L.; Chandrasekhar, J.; Madura, J.D.; Impey, R.W.; Klein, M.L. Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* **1983**, *79*, 926.

52. Krieger, E.; Dunbrack, R.L.; Hooft, R.W.W.; Krieger, B. Assignment of protonation states in proteins and ligands: Combining pKₐ prediction with hydrogen bonding network optimization. *Methods Mol. Biol.* **2012**, *819*, 405–421.

53. Essmann, U.; Perera, L.; Berkowitz, M.L.; Darden, T.; Lee, H.; Pedersen, L.G. A smooth particle mesh Ewald method. *J. Chem. Phys.* **1995**, *103*, 8577.

54. Saenz-Méndez, P.; Elmabsout, A.A.; Sävenstrand, H.; Awadalla, M.K.A.; Strid, Å.; Sirsjö, A.; Eriksson, L.A. Homology models of human all-trans retinoic acid metabolizing enzymes CYP26B1 and CYP26B1 spliced variant. *J. Chem. Inf. Model.* **2012**, *52*, 2631–2637.

55. Decroos, C.; Bowman, C.M.; Moser, J.-A.S.; Christianson, K.E.; Deardorff, M.A.; Christianson, D.W. Compromised structure and function of HDAC8 mutants identified in cornelia de lange syndrome spectrum disorders. *ACS Chem. Biol.* **2014**, *9*, 2157–2164.

56. Lauffer, B.E.L.; Mintzer, R.; Fong, R.; Mukund, S.; Tam, C.; Zilberleyb, I.; Flicke, B.; Ritscher, A.; Fedorowicz, G.; Vallero, R.; *et al.* Histone deacetylase (HDAC) inhibitor kinetic rate constants correlate with cellular histone acetylation but not transcription and cell viability. *J. Biol. Chem.* **2013**, *288*, 26926–26943.

© 2015 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).